Genenta Science S.p.A (GNTA) Accumulated Expenses (2020 - 2025)
Genenta Science S.p.A (GNTA) posted Accumulated Expenses of $90995.6 for Q4 2025, down 65.16% sequentially from $261156.7 in Q2 2025, and down 91.74% YoY from $1.1 million in Q4 2024.
Genenta Science S.p.A (GNTA) Accumulated Expenses (2020 - 2025) Analysis & Trends
Genenta Science S.p.A has reported Accumulated Expenses for 6 years, with the latest figure at $90995.6 in Q4 2025.
- Quarterly Accumulated Expenses fell 91.74% year-over-year to $90995.6 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $90995.6 (down 91.74% YoY) and the FY2025 annual result came in at $90995.6, down 91.74% from the prior year.
- Accumulated Expenses fell to $90995.6 in Q4 2025 per GNTA's latest filing, from $261156.7 in the prior quarter.
- Over five years, Accumulated Expenses peaked at $1.1 million in Q4 2024 and troughed at $90995.6 in Q4 2025.
- A 5-year average of $542364.4 and a median of $499112.2 in 2022 frame the typical range for Accumulated Expenses.
- The sharpest annual moves came in 2022 and 2025: Accumulated Expenses soared 230.18% in 2022, then slumped 91.74% in 2025.
- Over 5 years, Accumulated Expenses stood at $151165.5 in 2021, then jumped by 230.18% to $499112.2 in 2022, then soared by 85.73% to $927006.2 in 2023, then climbed by 18.89% to $1.1 million in 2024, then plunged by 91.74% to $90995.6 in 2025.
- According to Business Quant data, Accumulated Expenses over the past three periods registered $90995.6, $261156.7, and $1.1 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Genenta Science S.p.A | 25.03 Mn | -34.07 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 90,995.61 |
| Jun 30, 2025 | 261,156.68 |
| Dec 31, 2024 | 1.10 Mn |
| Jun 30, 2024 | 752,602.27 |
| Dec 31, 2023 | 927,006.15 |
| Jun 30, 2023 | 688,615.10 |
| Dec 31, 2022 | 499,112.15 |
| Jun 30, 2022 | 408,535.46 |
| Dec 31, 2021 | 151,165.47 |
| Dec 31, 2020 | 436,341.12 |